Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 11 hours ago
FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
about 11 hours ago
The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer...
FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board
about 12 hours ago
The FDA today announced a new initiative to allow its reviewers to...
Protagonist opts for $475M in Takeda payouts instead of splitting US rusfertide profits
about 15 hours ago
After mulling its options for the past few months, Protagonist Therapeutics has...
AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition
about 15 hours ago
AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics...
Incyte’s JAK inhibitor scores phase 3 vitiligo wins but can’t quite shake off Rinvoq
about 16 hours ago
Incyte’s povorcitinib has scored a pair of phase 3 wins for a...
Erasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death
about 16 hours ago
Erasca has backed up bullish claims about its pan-RAS drug having a...
Lilly pens $2.2B pact with Bezos-backed Profluent to work on recombinase-based gene editing
about 17 hours ago
Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen...
Medtronic thwarts cyberattack on its IT systems in wake of data breach at Stryker
about 18 hours ago
Medtronic, the largest medical device maker in the world, said it contained...
Rebranded Belgian biotech lands $125M for rescued Galapagos drug candidates
about 19 hours ago
After launching in 2025 as a refuge for shipwrecked assets from Galapagos...
Merck KGaA, Remepy team up on software-enhanced hybrid drugs for rare tumors
about 19 hours ago
German drugmaker Merck KGaA is teaming up with Israeli biotech Remepy to...
Janux axes solid tumor T-cell engager after poor phase 1 showing
about 21 hours ago
After a disappointing phase 1 showing, Janux Therapeutics is kicking one of...
Boehringer links dual agonist to 16.6% weight loss in phase 3, but leaves key questions unanswered
about 22 hours ago
While the result fell short of the bar set by existing drugs...